← Oncology Approval Tracker

FDA DECISION ·

Noxafil delayed-release tablets / injection

posaconazole · Merck

FDA approvalNew or expanded indicationInvasive fungal infection prophylaxis
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Extends prophylaxis of invasive Aspergillus and Candida infections to high-risk pediatric patients age 2 and older, including specified transplant and hematologic malignancy populations. The delayed-release tablet use applies above 40 kg, while the injection expansion has no corresponding weight cutoff in the approval letter.

LAMPGEN ANALYSIS

Why it matters

These supplements extend existing oral and intravenous options to younger immunocompromised patients.

What research teams should watch

Record weight, route, transplant or neutropenia risk and the specific formulation in the prophylaxis plan.

PRIMARY RECORDS

Sources